{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:05:39Z","timestamp":1780484739093,"version":"3.54.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02015-1","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:48:34Z","timestamp":1772016514000},"page":"1759-1788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR\/Cas9 in Cancer Therapy: Precision Genome Editing Approaches Targeting Hematological Malignancies and Solid Tumors Through Cellular, Biochemical, and Molecular Mechanisms"],"prefix":"10.1007","volume":"84","author":[{"given":"Disha","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Kshatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-9063","authenticated-orcid":false,"given":"Kaushika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"4","key":"2015_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","volume":"101","author":"M Redman","year":"2016","unstructured":"Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR\/Cas9? Archives of Disease in Childhood: Education and Practice Edition, 101(4), 213\u2013215. https:\/\/doi.org\/10.1136\/archdischild-2016-310459","journal-title":"Archives of Disease in Childhood: Education and Practice Edition"},{"key":"2015_CR2","doi-asserted-by":"publisher","unstructured":"Ishino, Y., Krupovic, M., & Forterre, P. (2018). History of CRISPR-Cas from encounter with a mysterious repeated sequence to genome editing technology. Journal of Bacteriology, 200(7). https:\/\/doi.org\/10.1128\/JB.00580-17","DOI":"10.1128\/JB.00580-17"},{"key":"2015_CR3","doi-asserted-by":"publisher","unstructured":"van der Oost, J., & Patinios, C. (2023, March 1). The genome editing revolution. Trends in Biotechnology. Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.tibtech.2022.12.022","DOI":"10.1016\/j.tibtech.2022.12.022"},{"issue":"1","key":"2015_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-021-01431-6","volume":"20","author":"H. Zhang","year":"2021","unstructured":"Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., & Wu, Y. (2021). Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Molecular Cancer, 20(1), 126. https:\/\/doi.org\/10.1186\/s12943-021-01431-6","journal-title":"Molecular Cancer"},{"key":"2015_CR5","doi-asserted-by":"publisher","unstructured":"Yahya, E. B., & Alqadhi, A. M. (2021). Recent trends in cancer therapy: A review on the current state of gene delivery. Life Sciences, 269, 119087. https:\/\/doi.org\/10.1016\/j.lfs.2021.119087","DOI":"10.1016\/j.lfs.2021.119087"},{"issue":"11","key":"2015_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","volume":"13","author":"KS Makarova","year":"2015","unstructured":"Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., & Saunders, S. J. (2015). E. V. (Ed.), An updated evolutionary classification of CRISPR-Cas systems. Nature Reviews Microbiology 13 11 722\u2013736 https:\/\/doi.org\/10.1038\/nrmicro3569.","journal-title":"Nature Reviews Microbiology"},{"key":"2015_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S13353-025-00979-Z","volume":"2025","author":"J Sharma","year":"2025","unstructured":"Sharma, J., Biswas, R., & Khare, P. (2025). Design principle of successful genome editing applications using CRISPR-based toolkits. Journal of Applied Genetics, 2025, 1\u201313. https:\/\/doi.org\/10.1007\/S13353-025-00979-Z","journal-title":"Journal of Applied Genetics"},{"key":"2015_CR8","doi-asserted-by":"publisher","unstructured":"Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019, April 1). CRISPR\/Cas9 for cancer research and therapy. Seminars in Cancer Biology. Academic Press. https:\/\/doi.org\/10.1016\/j.semcancer.2018.04.001","DOI":"10.1016\/j.semcancer.2018.04.001"},{"key":"2015_CR9","doi-asserted-by":"publisher","unstructured":"Luther, D. C., Lee, Y. W., Nagaraj, H., Scaletti, F., & Rotello, V. M. (2018). September 2). Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: Advances and challenges. Expert opinion on drug delivery. Taylor and Francis Ltd. https:\/\/doi.org\/10.1080\/17425247.2018.1517746","DOI":"10.1080\/17425247.2018.1517746"},{"issue":"7","key":"2015_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41580-025-00828-1","volume":"2025 26:7","author":"I Chiolo","year":"2025","unstructured":"Chiolo, I., Altmeyer, M., Legube, G., & Mekhail, K. (2025). Nuclear and genome dynamics underlying DNA double-strand break repair. Nature Reviews Molecular Cell Biology, 2025 26:7(7), 538\u2013557. https:\/\/doi.org\/10.1038\/s41580-025-00828-1. 26.","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"2015_CR11","doi-asserted-by":"publisher","unstructured":"Shojaei Baghini, S., Gardanova, Z. R., Abadi, S. A. H., Zaman, B. A., \u0130lhan, A.,Shomali, N., Yaseri, A. F. (2022, December 1). CRISPR\/Cas9 application in cancer therapy: a pioneering genome editing tool. Cellular and Molecular Biology Letters. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s11658-022-00336-6","DOI":"10.1186\/s11658-022-00336-6"},{"key":"2015_CR12","doi-asserted-by":"publisher","unstructured":"Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021, September 1). Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment. Advanced Drug Delivery Reviews. Elsevier B.V. https:\/\/doi.org\/10.1016\/j.addr.2021.113891","DOI":"10.1016\/j.addr.2021.113891"},{"key":"2015_CR13","doi-asserted-by":"publisher","unstructured":"Garg, P., Singhal, G., Pareek, S., Kulkarni, P., Horne, D., Nath, A., \u2026 Singhal,S. S. (2025). Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(1), 189233. https:\/\/doi.org\/10.1016\/J.BBCAN.2024.189233.","DOI":"10.1016\/J.BBCAN.2024.189233."},{"key":"2015_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/J.OMTN.2022.12.016","volume":"31","author":"GL Gregory","year":"2023","unstructured":"Gregory, G. L., & Copple, I. M. (2023). Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Molecular Therapy - Nucleic Acids, 31, 211\u2013223. https:\/\/doi.org\/10.1016\/J.OMTN.2022.12.016","journal-title":"Molecular Therapy - Nucleic Acids"},{"issue":"7","key":"2015_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/J.TEM.2024.08.009","volume":"36","author":"X Wang","year":"2025","unstructured":"Wang, X., Zhang, S., Xue, D., Neculai, D., & Zhang, J. (2025). Metabolic reprogramming of macrophages in cancer therapy. Trends in Endocrinology & Metabolism, 36(7), 660\u2013676. https:\/\/doi.org\/10.1016\/J.TEM.2024.08.009","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"2015_CR16","doi-asserted-by":"publisher","unstructured":"Ding, Y., Denomy, C., Freywald, A., Pan, Y., Vizeacoumar, F. J., Vizeacoumar, F. S., & Wu, F. X. (2024). Systematic Comparison of CRISPR and shRNA Screens to Identify Essential Genes Using a Graph-Based Unsupervised Learning Model. Cells, 13(19). https:\/\/doi.org\/10.3390\/CELLS13191653\/S1","DOI":"10.3390\/CELLS13191653\/S1"},{"key":"2015_CR17","doi-asserted-by":"publisher","unstructured":"Park, H., Yu, S., & Koo, T. (2025). Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine. Cancer Gene Therapy 2025, 1\u201310. https:\/\/doi.org\/10.1038\/s41417-025-00959-9","DOI":"10.1038\/s41417-025-00959-9"},{"issue":"1,22(1","key":"2015_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12935-022-02654-3","volume":"22","author":"V. Karn","year":"2022","unstructured":"Karn, V., Sandhya, S., Hsu, W., Parashar, D., Singh, H. N., Jha, N. K., & Kumar, S. (2022). CRISPR\/Cas9 system in breastcancer therapy: advancement, limitations and future scope. Cancer Cell International, 22(1), 234. https:\/\/doi.org\/10.1186\/s12935-022-02654-3","journal-title":"Cancer Cell International"},{"issue":"5","key":"2015_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.tips.2025.02.009","volume":"46","author":"K. C. Wang","year":"2025","unstructured":"Wang, K. C., Zheng, T., & Hubbard, B. P. (2025). CRISPR\/Cas technologies for cancer drug discovery and treatment. Trends in Pharmacological Sciences, 46(5), 437\u2013452. https:\/\/doi.org\/10.1016\/J.TIPS.2025.02.009","journal-title":"Trends in Pharmacological Sciences"},{"key":"2015_CR20","doi-asserted-by":"publisher","unstructured":"Wang, S. W., Gao, C., Zheng, Y. M., Yi, L., Lu, J. C., Huang, X. Y., \u2026 Ke, A. W. (2022). Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer. Molecular Cancer 2022 21:1, 21(1), 57 https:\/\/doi.org\/10.1186\/S12943-022-01518-8","DOI":"10.1186\/S12943-022-01518-8"},{"key":"2015_CR21","doi-asserted-by":"publisher","unstructured":"Lee, W., Lee, J. H., Jun,S., Lee, J. H., & Bang, D. (2018). Selective targeting of KRAS oncogenic alleles by CRISPR\/Cas9inhibits proliferation of cancer cells. Scientific Reports, 8(1). https:\/\/doi.org\/10.1038\/s41598-018-30205-2","DOI":"10.1038\/s41598-018-30205-2"},{"key":"2015_CR22","doi-asserted-by":"publisher","unstructured":"Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024). Patient-derived organoids: a promising tool for breast cancer research. Frontiers in Oncology, 14, 1350935. https:\/\/doi.org\/10.3389\/FONC.2024.1350935\/BIBTEX","DOI":"10.3389\/FONC.2024.1350935\/BIBTEX"},{"issue":"1","key":"2015_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-62350-4","volume":"16","author":"J. C. \u00c1lvarez-P\u00e9rez","year":"2025","unstructured":"\u00c1lvarez-P\u00e9rez, J. C., Sanju\u00e1n-Hidalgo, J., Arenas, A. M., Hern\u00e1ndez-Navas, I., Benitez-Cantos,M. S., Andrades, A., \u2026 Medina, P. P. (2025). High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models. Nature Communications, 16(1), 1\u201314. https:\/\/doi.org\/10.1038\/s41467-025-62350-4","journal-title":"Nature Communications"},{"issue":"6","key":"2015_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","volume":"2025 24:6","author":"JR Whitfield","year":"2025","unstructured":"Whitfield, J. R., & Soucek, L. (2025). MYC in cancer: From undruggable target to clinical trials. Nature Reviews Drug Discovery, 2025 24:6(6), 445\u2013457. https:\/\/doi.org\/10.1038\/s41573-025-01143-2. 24.","journal-title":"Nature Reviews Drug Discovery"},{"key":"2015_CR25","doi-asserted-by":"publisher","unstructured":"Duffy, M. J., O\u2019Grady, S., Tang, M., & Crown, J. (2021). March 1). MYC as a target for cancer treatment. Cancer treatment reviews. W.B. Saunders Ltd. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102154","DOI":"10.1016\/j.ctrv.2021.102154"},{"issue":"11","key":"2015_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/1878-0261.13493","volume":"17","author":"M. Kazimierska","year":"2023","unstructured":"Kazimierska, M., Podralska, M., \u017burawek, M., Wo\u017aniak, T., Kasprzyk, M. E., Sura, W., & Dzikiewicz-Krawczyk, A. (2023). CRISPR\/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells. Molecular Oncology, 17(11), 2295\u20132313. https:\/\/doi.org\/10.1002\/1878-0261.13493","journal-title":"Molecular Oncology"},{"key":"2015_CR27","doi-asserted-by":"publisher","unstructured":"Tanaka, Y., Kambayashi, H., Yamamoto, A., Onishi, I., Sugita, K., Matsumura, M.,\u2026 Kurata, M. (2022). Efficient Identification of the MYC Regulator with the Use of the CRISPR Library and Context-Matched Database Screenings. International Journal of Molecular Sciences, 23(14), 7723. https:\/\/doi.org\/10.3390\/IJMS23147723\/S1.","DOI":"10.3390\/IJMS23147723\/S1."},{"key":"2015_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.omtn.2017.05.009","volume":"8","author":"M Yang","year":"2017","unstructured":"Yang, M., Wei, H., Wang, Y., Deng, J., Tang, Y., Zhou, L., & Tong, A. (2017). Targeted disruption of V600E-Mutant BRAF gene by CRISPR-Cpf1. Molecular Therapy Nucleic Acids, 8, 450\u2013458. https:\/\/doi.org\/10.1016\/j.omtn.2017.05.009","journal-title":"Molecular Therapy Nucleic Acids"},{"key":"2015_CR29","doi-asserted-by":"publisher","unstructured":"Wu, X., Huang, H., Yu, B., & Zhang, J. (2020). A blue Light-Inducible CRISPR-Cas9 system for inhibiting progression of melanoma cells. Frontiers in Molecular Biosciences, 7. https:\/\/doi.org\/10.3389\/fmolb.2020.606593","DOI":"10.3389\/fmolb.2020.606593"},{"key":"2015_CR30","doi-asserted-by":"publisher","unstructured":"Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D.,\u2026 Simeone, E. (2021, April 1). BRAF gene and melanoma: Back to the future. International Journal of Molecular Sciences. MDPI AG. https:\/\/doi.org\/10.3390\/ijms22073474.","DOI":"10.3390\/ijms22073474."},{"key":"2015_CR31","doi-asserted-by":"publisher","unstructured":"Gopal, P., Sarihan, E. I., Chie, E. K., Kuzmishin, G., Doken, S., Pennell, N. A.,\u2026 Abazeed, M. E. (2019). Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. Nature Communications, 10(1). https:\/\/doi.org\/10.1038\/s41467-019-13161-x.","DOI":"10.1038\/s41467-019-13161-x."},{"key":"2015_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25101","author":"A Etemadzadeh","year":"2024","unstructured":"Etemadzadeh, A., Salehipour, P., Motlagh, F. M., Khalifeh, M., Asadbeigi, A., Tabrizi, M., & Modarressi, M. H. (2024). An optimized CRISPR\/Cas12a assay to facilitate the BRAF V600E mutation detection. Journal of Clinical Laboratory Analysis. https:\/\/doi.org\/10.1002\/jcla.25101","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"2015_CR33","doi-asserted-by":"publisher","unstructured":"Uribe, M. L., Marrocco, I., & Yarden, Y. (2021). cancers EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. https:\/\/doi.org\/10.3390\/cancers","DOI":"10.3390\/cancers"},{"key":"2015_CR34","doi-asserted-by":"publisher","unstructured":"Cheung, A. H. K., Chow, C., Zhang, J., Zhou, Y., Huang, T., Ng, K. C. K., \u2026 To, K.F. (2018). Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR\/Cas9. Laboratory Investigation, 98(7), 968\u2013976. https:\/\/doi.org\/10.1038\/s41374-018-0056-1.","DOI":"10.1038\/s41374-018-0056-1."},{"key":"2015_CR35","doi-asserted-by":"publisher","unstructured":"Mirgayazova, R., Khadiullina, R., Chasov, V., Mingaleeva, R., Miftakhova, R., Rizvanov, A., & Bulatov, E. (2020, June 1). Therapeutic editing of the TP53 gene: Is crispr\/CAS9 an option? Genes. MDPI AG. https:\/\/doi.org\/10.3390\/genes11060704","DOI":"10.3390\/genes11060704"},{"issue":"11","key":"2015_CR36","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","volume":"13","author":"KS Makarova","year":"2015","unstructured":"Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., & Koonin, E. V. (2015). An updated evolutionary classification of CRISPR-Cas systems. Nature Reviews Microbiology, 13(11), 722\u2013736. https:\/\/doi.org\/10.1038\/nrmicro3569","journal-title":"Nature Reviews Microbiology"},{"issue":"4","key":"2015_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/mco2.106","volume":"2","author":"ZN Lei","year":"2021","unstructured":"Lei, Z. N., Teng, Q. X., Wu, Z. X., Ping, F. F., Song, P., Wurpel, J. N. D., & Chen, Z. S. (2021). Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR\/Cas9 system in SW620\/Ad300 colorectal cancer cells. MedComm, 2(4), 765\u2013777. https:\/\/doi.org\/10.1002\/mco2.106","journal-title":"MedComm"},{"key":"2015_CR38","doi-asserted-by":"publisher","unstructured":"Maroufi, F., Maali, A., Abdollahpour-Alitappeh, M., Ahmadi, M. H., & Azad, M. (2020, October 1). CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy. Epigenomics. Future Medicine Ltd. https:\/\/doi.org\/10.2217\/epi-2020-0110","DOI":"10.2217\/epi-2020-0110"},{"key":"2015_CR39","doi-asserted-by":"publisher","unstructured":"Li, J., Mahata, B., Escobar, M., Goell, J., Wang, K., Khemka, P., & Hilton, I. B. (2021). Programmable human histone phosphorylation and gene activation using a CRISPR\/Cas9-based chromatin kinase. Nature Communications, 12(1). https:\/\/doi.org\/10.1038\/s41467-021-21188-2","DOI":"10.1038\/s41467-021-21188-2"},{"key":"2015_CR40","doi-asserted-by":"publisher","unstructured":"Xie, N., Zhou, Y., Sun, Q., & Tang, B. (2018). Novel epigenetic techniques provided by the CRISPR\/Cas9 system. Stem Cells International, 2018. https:\/\/doi.org\/10.1155\/2018\/7834175","DOI":"10.1155\/2018\/7834175"},{"key":"2015_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010573","author":"K Balon","year":"2022","unstructured":"Balon, K., Sheriff, A., Jack\u00f3w, J., & \u0141aczma\u0144ski, \u0141. (2022). January 1). Targeting cancer with CRISPR\/Cas9-Based therapy. International Journal of Molecular Sciences MDPI. https:\/\/doi.org\/10.3390\/ijms23010573","journal-title":"International Journal of Molecular Sciences MDPI"},{"issue":"24","key":"2015_CR42","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/0008-5472.CAN-17-2142","volume":"77","author":"G Aquino-Jarquin","year":"2017","unstructured":"Aquino-Jarquin, G. (2017). Emerging role of CRISPR\/Cas9 technology for MicroRNAs editing in cancer research. Cancer Research, 77(24), 6812\u20136817. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2142","journal-title":"Cancer Research"},{"key":"2015_CR43","unstructured":"Rosenlund, I. A., Calin, G. A., Dragomir, M. P., & Knutsen, E. (n.d.). CRISPR\/Cas9 to silence long non-coding RNAs."},{"key":"2015_CR44","doi-asserted-by":"publisher","unstructured":"Zhen, S., & Li, X. (2019, January 1). Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research. Human Gene Therapy. Mary Ann Liebert Inc. https:\/\/doi.org\/10.1089\/hum.2018.063","DOI":"10.1089\/hum.2018.063"},{"key":"2015_CR45","doi-asserted-by":"publisher","unstructured":"Tebbi, C. K. (2021, May 1). Etiology of acute leukemia: A review. Cancers. MDPI. https:\/\/doi.org\/10.3390\/cancers13092256","DOI":"10.3390\/cancers13092256"},{"key":"2015_CR46","doi-asserted-by":"publisher","unstructured":"Lo Schiavo, F., Salvesi, C., Jandoubi, M., Pirini, F., Garbetta, J., Martinelli,G., \u2026 Ferrari, A. (2025). Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.Molecular Cancer 2025 24:1, 24(1), 1\u201325. https:\/\/doi.org\/10.1186\/S12943-025-02455-Y.","DOI":"10.1186\/S12943-025-02455-Y."},{"issue":"1","key":"2015_CR47","doi-asserted-by":"publisher","first-page":"e22095","DOI":"10.1016\/j.heliyon.2023.e22095","volume":"10","author":"EO Mahgoub","year":"2024","unstructured":"Mahgoub, E. O., Cho, W. C., Sharifi, M., Falahati, M., Zeinabad, H. A., Mare, H. E., & Hasan, A. (2024). Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse. Heliyon, 10(1), e22095. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22095","journal-title":"Heliyon"},{"key":"2015_CR48","doi-asserted-by":"publisher","unstructured":"Dengler, M. A., Teh, C. E., Thijssen, R., Gangoda, L., Lan, P., Herold, M. J., \u2026Adams, J. M. (2020). Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene, 39(9), 2009\u20132023. https:\/\/doi.org\/10.1038\/S41388-019-1122-X;TECHMETA.","DOI":"10.1038\/S41388-019-1122-X;TECHMETA."},{"key":"2015_CR49","doi-asserted-by":"publisher","unstructured":"Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S. S., & Chakraborty, C. (2021). February 3). CRISPR-Cas9: A preclinical and clinical perspective for the treatment of human diseases. Molecular therapy. Cell. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.028","DOI":"10.1016\/j.ymthe.2020.09.028"},{"issue":"3","key":"2015_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5507\/bp.2021.048","volume":"165","author":"RG Mihaila","year":"2021","unstructured":"Mihaila, R. G., & Topircean, D. (2021). The high-performance technology crispr\/cas9 improves knowledge and management of acute myeloid leukemia. Biomedical Papers, 165(3), 249\u2013257. https:\/\/doi.org\/10.5507\/bp.2021.048","journal-title":"Biomedical Papers"},{"key":"2015_CR51","doi-asserted-by":"publisher","unstructured":"Yang, F. C., & Agosto-Pe\u00f1a, J. (2023). Epigenetic regulation by ASXL1 in myeloid malignancies. International Journal of Hematology 2023 117:6, 117(6), 791\u2013806. https:\/\/doi.org\/10.1007\/S12185-023-03586-Y","DOI":"10.1007\/S12185-023-03586-Y"},{"key":"2015_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1322937","author":"AJB Assis","year":"2023","unstructured":"Assis, A. J. B., Santana, B. L., de Gualberto, O., A. C. M., & Pittella-Silva, F. (2023). Therapeutic applications of CRISPR\/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: Current perspectives, future challenges, and clinical implications. Frontiers in Pharmacology Frontiers Media SA. https:\/\/doi.org\/10.3389\/fphar.2023.1322937","journal-title":"Frontiers in Pharmacology Frontiers Media SA"},{"key":"2015_CR53","doi-asserted-by":"publisher","unstructured":"Xie, F., Zhang, T. J., Zhang, X. L., Xu, Z. J., Qiao, L., Wang, Y., Zhou, J. D. (2025). Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia. BMC Cancer 2025 25:1, 25(1), 215 https:\/\/doi.org\/10.1186\/S12885-025-13633-Y","DOI":"10.1186\/S12885-025-13633-Y"},{"issue":"2","key":"2015_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jor.22745","volume":"33","author":"Y Feng","year":"2015","unstructured":"Feng, Y., Sassi, S., Shen, J. K., Yang, X., Gao, Y., Osaka, E., & Duan, Z. (2015). Targeting Cdk11 in osteosarcoma cells using the CRISPR-cas9 system. Journal of Orthopaedic Research, 33(2), 199\u2013207. https:\/\/doi.org\/10.1002\/jor.22745","journal-title":"Journal of Orthopaedic Research"},{"key":"2015_CR55","doi-asserted-by":"publisher","unstructured":"Heshmatpour, N., Kazemi, S. M., Schmidt, N. D., Patnaik, S. R., Korus, P., Wilkens, B. G. C., & Macarr\u00f3n Palacios, A. (2024). Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes. Frontiers in Genome Editing, 6. https:\/\/doi.org\/10.3389\/fgeed.2024.1427322","DOI":"10.3389\/fgeed.2024.1427322"},{"key":"2015_CR56","doi-asserted-by":"publisher","unstructured":"Guo, Y., Tong, C., Su, L., Zhang, W., Jia, H., Liu, Y., \u2026 Han, W. (2022, April 26).CRISPR\/Cas9 genome-edited universal CAR T cells in patients with relapsed\/refractory lymphoma. Blood Advances. American Society of Hematology. https:\/\/doi.org\/10.1182\/bloodadvances.2021006232.","DOI":"10.1182\/bloodadvances.2021006232."},{"key":"2015_CR57","doi-asserted-by":"publisher","unstructured":"Escriv\u00e1-Fern\u00e1ndez, J., Cueto-Ure\u00f1a, C., Solana-Orts, A., Lled\u00f3, E., Ballester-Lurbe, B., & Poch, E. (2023). A CRISPR interference strategy for gene expression Silencing in multiple myeloma cell lines. Journal of Biological Engineering, 17(1). https:\/\/doi.org\/10.1186\/s13036-023-00347-7","DOI":"10.1186\/s13036-023-00347-7"},{"key":"2015_CR58","doi-asserted-by":"publisher","unstructured":"Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., \u2026 Ajebo,G. H. (2021, January 20). Epidemiology, Staging, and Management of Multiple Myeloma.Medical sciences (Basel, Switzerland). NLM (Medline). https:\/\/doi.org\/10.3390\/medsci9010003.","DOI":"10.3390\/medsci9010003."},{"key":"2015_CR59","doi-asserted-by":"publisher","unstructured":"Bohl, S. R., Schmalbrock, L. K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., \u2026Kr\u00f6nke, J. (2021). Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Advances, 5(9), 2391\u20132402. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020003541.","DOI":"10.1182\/BLOODADVANCES.2020003541."},{"key":"2015_CR60","doi-asserted-by":"publisher","unstructured":"Khaled, M., Moustafa, A. S., El-Khazragy, N., Ahmed, M. I., Abd Elkhalek, A., M., & Salahy, E., E. M (2021). CRISPR\/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells. Plos One, 16(1 January). https:\/\/doi.org\/10.1371\/journal.pone.0245349","DOI":"10.1371\/journal.pone.0245349"},{"key":"2015_CR61","doi-asserted-by":"publisher","unstructured":"Bexte, T., Alzubi, J., Reindl, L. M., Wendel, P., Schubert, R., Salzmann-Manrique,E., \u2026 Ullrich, E. (2022). CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma. OncoImmunology, 11(1). https:\/\/doi.org\/10.1080\/2162402X.2022.2081415.","DOI":"10.1080\/2162402X.2022.2081415."},{"key":"2015_CR62","doi-asserted-by":"publisher","unstructured":"Chen, Y., & Zhang, Y. (2018, June 1). Application of the CRISPR\/Cas9 System to Drug Resistance in Breast Cancer. Advanced Science. John Wiley and Sons Inc. https:\/\/doi.org\/10.1002\/advs.201700964","DOI":"10.1002\/advs.201700964"},{"key":"2015_CR63","doi-asserted-by":"publisher","unstructured":"Burguin, A., Diorio, C., & Durocher, F. (2021). Breast cancer treatments: Updates and new challenges. Journal of Personalized Medicine, 11(8). https:\/\/doi.org\/10.3390\/jpm11080808","DOI":"10.3390\/jpm11080808"},{"key":"2015_CR64","doi-asserted-by":"publisher","unstructured":"Mao, Y., Yang, D., He, J., & Krasna, M. J. (2016). Epidemiology of lung cancer. Surgical oncology clinics of North America. W.B. Saunders. https:\/\/doi.org\/10.1016\/j.soc.2016.02.001","DOI":"10.1016\/j.soc.2016.02.001"},{"issue":"10","key":"2015_CR65","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath, M. B., & Cote, M. L. (2019). Cancer progress and priorities: Lung cancer. Cancer Epidemiology Biomarkers and Prevention, 28(10), 1563\u20131579. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0221","journal-title":"Cancer Epidemiology Biomarkers and Prevention"},{"key":"2015_CR66","doi-asserted-by":"publisher","unstructured":"Mitra, S., Sarker, J., Mojumder, A., Shibbir, T. B., Das, R., Emran, T. Bin, \u2026 Simal-Gandara,J. (2022, June 1). Genome editing and cancer: How far has research moved forward on CRISPR\/Cas9? Biomedicine and Pharmacotherapy. Elsevier Masson s.r.l. https:\/\/doi.org\/10.1016\/j.biopha.2022.113011.","DOI":"10.1016\/j.biopha.2022.113011."},{"key":"2015_CR67","doi-asserted-by":"publisher","unstructured":"Liu, B., Wang, Z., Gu, M., Wang, J., & Tan, J. (2024, August 31). Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review. Translational Lung Cancer Research. AME Publishing Company. https:\/\/doi.org\/10.21037\/tlcr-24-592","DOI":"10.21037\/tlcr-24-592"},{"key":"2015_CR68","doi-asserted-by":"publisher","unstructured":"Liu, B., Saber, A., & Haisma, H. J. (2019, April 1). CRISPR\/Cas9: a powerful tool for identification of new targets for cancer treatment. Drug Discovery Today. Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.drudis.2019.02.011","DOI":"10.1016\/j.drudis.2019.02.011"},{"key":"2015_CR69","doi-asserted-by":"publisher","unstructured":"Lee, J., Choi, A., Cho, S. Y., Jun, Y., Na, D., Lee, A., Lee, C. (2021). Genome-scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib-resistant lung cancer. Molecular Oncology, 15(2), 487\u2013502 https:\/\/doi.org\/10.1016\/j.drudis.2019.02.011","DOI":"10.1016\/j.drudis.2019.02.011"},{"key":"2015_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010197","author":"I M\u00e1rmol","year":"2017","unstructured":"M\u00e1rmol, I., S\u00e1nchez-de-Diego, C., Dieste, A. P., Cerrada, E., & Yoldi, M. J. R. (2017). January 19). Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. International Journal of Molecular Sciences MDPI AG. https:\/\/doi.org\/10.3390\/ijms18010197","journal-title":"International Journal of Molecular Sciences MDPI AG"},{"key":"2015_CR71","doi-asserted-by":"publisher","unstructured":"Granados-Romero, J. J., Valderrama-Trevi\u00f1o, A. I., Contreras-Flores, E. H., Barrera-Mera,B., Herrera Enr\u00edquez, M., Uriarte-Ru\u00edz, K., \u2026 Arauz-Pe\u00f1a, G. (2017). Colorectal cancer:a review. International Journal of Research in Medical Sciences, 5(11), 4667. https:\/\/doi.org\/10.18203\/2320-6012.ijrms20174914.","DOI":"10.18203\/2320-6012.ijrms20174914."},{"key":"2015_CR72","doi-asserted-by":"publisher","unstructured":"Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., \u2026 Song, Z. (2023, March 1).The application and progression of CRISPR\/Cas9 technology in ophthalmological diseases.Eye (Basingstoke). Springer Nature. https:\/\/doi.org\/10.1038\/s41433-022-02169-1.","DOI":"10.1038\/s41433-022-02169-1."},{"key":"2015_CR73","doi-asserted-by":"publisher","unstructured":"Liu, Z., Li, Y., Wang, S., Wang, Y., Sui, M., Liu, J., Hou, P. (2025). Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. Journal of Experimental & Clinical Cancer Research 2025 44:1, 44(1), 70 https:\/\/doi.org\/10.1053\/j.gastro.2020.10.007.","DOI":"10.1053\/j.gastro.2020.10.007."},{"key":"2015_CR74","doi-asserted-by":"publisher","unstructured":"Huang, J., Lok, V., Ngai, C. H., Zhang, L., Yuan, J., Lao, X. Q., \u2026 Wong, M. C. S.(2021). Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology, 160(3), 744\u2013754. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.007.","DOI":"10.1053\/j.gastro.2020.10.007."},{"key":"2015_CR75","doi-asserted-by":"publisher","unstructured":"Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011). Pancreatic cancer. In The Lancet (Vol. 378, pp. 607\u2013620). Elsevier B.V. https:\/\/doi.org\/10.1016\/S0140-6736(10)62307-0","DOI":"10.1016\/S0140-6736(10)62307-0"},{"key":"2015_CR76","doi-asserted-by":"publisher","unstructured":"Teh, S. S. K., Bowland, K., Halper-Stromberg, E., Kotwal, A., Bennett, A., Skaist,A., \u2026 Eshleman, J. R. (2024). CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers. NAR Cancer, 6(2). https:\/\/doi.org\/10.1093\/narcan\/zcae028.","DOI":"10.1093\/narcan\/zcae028."},{"key":"2015_CR77","doi-asserted-by":"publisher","unstructured":"Martinez, S., Wu, S., Geuenich, M., Malik, A., Weber, R., Woo, T., \u2026 Schramek, D.(2024). In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer.Nature Communications, 15(1). https:\/\/doi.org\/10.1038\/s41467-024-49450-3.","DOI":"10.1038\/s41467-024-49450-3."},{"key":"2015_CR78","doi-asserted-by":"publisher","unstructured":"Zhang, J., Zhang, S., D\u00f6rflein, I., Ren, X., Pfeffer, S., Britzen-Laurent, N., \u2026Pilarsky, C. (2023). Impact of CRISPR\/Cas9-Mediated CD73 Knockout in Pancreatic Cancer.Cancers, 15(19). https:\/\/doi.org\/10.3390\/cancers15194842.","DOI":"10.3390\/cancers15194842."},{"key":"2015_CR79","doi-asserted-by":"publisher","unstructured":"Feng, X., Li, Z., Liu, Y., Chen, D., & Zhou, Z. (2024, December 1). CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Experimental Hematology and Oncology. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s40164-024-00570-y","DOI":"10.1186\/s40164-024-00570-y"},{"issue":"2","key":"2015_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World Journal of Oncology"},{"key":"2015_CR81","doi-asserted-by":"publisher","unstructured":"Cai, H., Zhang, B., Ahrenfeldt, J., Joseph, J. V., Riedel, M., Gao, Z., \u2026 Thomsen,M. K. (2024). CRISPR\/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam\/Cabs1 gene cluster expression. Nature Communications, 15(1). https:\/\/doi.org\/10.1038\/s41467-024-46370-0.","DOI":"10.1038\/s41467-024-46370-0."},{"key":"2015_CR82","doi-asserted-by":"publisher","unstructured":"Tabibian, M., Moghaddam, F. S., Motevaseli, E., & Ghafouri-Fard, S. (2024, October 17). Targeting mRNA-coding genes in prostate cancer using CRISPR\/Cas9 technology with a special focus on androgen receptor signaling. Cell Communication and Signaling. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12964-024-01833-1","DOI":"10.1186\/s12964-024-01833-1"},{"key":"2015_CR83","doi-asserted-by":"publisher","unstructured":"Fieni, C., Sorrentino, C., Ciummo, S. L., Fontana, A., Lotti, L. V., Scialis, S.,\u2026 Di Carlo, E. (2024). Immunoliposome-based targeted delivery of the CRISPR\/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival. Experimental and Molecular Medicine. https:\/\/doi.org\/10.1038\/s12276-024-01310-2.","DOI":"10.1038\/s12276-024-01310-2."},{"key":"2015_CR84","doi-asserted-by":"publisher","unstructured":"Mazidimoradi, A., Momenimovahed, Z., Allahqoli, L., Tiznobaik, A., Hajinasab, N., Salehiniya, H., & Alkatout, I. (2022). The global, regional and National epidemiology, incidence, mortality, and burden of ovarian cancer. Health Science Reports, 5(6). https:\/\/doi.org\/10.1002\/hsr2.936","DOI":"10.1002\/hsr2.936"},{"key":"2015_CR85","doi-asserted-by":"publisher","unstructured":"Mazidimoradi, A., Momenimovahed, Z., Allahqoli, L., Tiznobaik, A., Hajinasab, N., Salehiniya, H., & Alkatout, I. (2022). The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer. Health Science Reports, 5(6). https:\/\/doi.org\/10.3390\/cancers14092230.","DOI":"10.3390\/cancers14092230."},{"key":"2015_CR86","doi-asserted-by":"publisher","unstructured":"Huang, J., Chan, W. C., Ngai, C. H., Lok, V., Zhang, L., Lucero-Prisno, D. E., \u2026Wong, M. C. S. (2022). Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers, 14(9). https:\/\/doi.org\/10.3390\/cancers14092230.","DOI":"10.3390\/cancers14092230."},{"key":"2015_CR87","doi-asserted-by":"publisher","unstructured":"Huo, W., Zhao, Gg., Yin, J., Ouyang, X., Wang, Y., Yang, C., \u2026 Yue, J. (2017). Lentiviral CRISPR\/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. Journal of Cancer, 8(1), 57\u201364. https:\/\/doi.org\/10.7150\/jca.16723.","DOI":"10.7150\/jca.16723."},{"key":"2015_CR88","doi-asserted-by":"publisher","unstructured":"Zhang, L., Mo, J., Shi, H., Xiong, J., Aierken, Y., Chen, F., \u2026 Tan, K. (2024). CRISPR-Cas9 screening develops an epigenetic and transcriptional gene signature for risk stratification and target prediction in neuroblastoma. Frontiers in Cell and Developmental Biology, 12. https:\/\/doi.org\/10.3389\/fcell.2024.1433008.","DOI":"10.3389\/fcell.2024.1433008."},{"key":"2015_CR89","doi-asserted-by":"publisher","unstructured":"Fetahu, I. S., & Taschner-Mandl, S. (n.d.). Neuroblastoma and the epigenome. https:\/\/doi.org\/10.1007\/s10555-020-09946-y\/Published","DOI":"10.1007\/s10555-020-09946-y\/Published"},{"key":"2015_CR90","doi-asserted-by":"publisher","unstructured":"Zhou, H., Ye, P., Xiong, W., Duan, X., Jing, S., He, Y., Ye, Q. (2024). Genome-scale CRISPR-Cas9 screening in stem cells: theories, applications and challenges. Stem Cell Research & Therapy 2024 15:1, 15(1), 218 https:\/\/doi.org\/10.1007\/s10555-020-09946-y\/Published","DOI":"10.1007\/s10555-020-09946-y\/Published"},{"key":"2015_CR91","doi-asserted-by":"publisher","unstructured":"Li, M., Sun, J., & Shi, G. (2023). Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy. Frontiers in Cell and Developmental Biology, 11, 1220376 https:\/\/doi.org\/10.1007\/s10555-020-09946-y\/Published","DOI":"10.1007\/s10555-020-09946-y\/Published"},{"key":"2015_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.963780","author":"CC Cruz-G\u00e1lvez","year":"2022","unstructured":"Cruz-G\u00e1lvez, C. C., Ordaz-Favila, J. C., Villar-Calvo, V. M., Cancino-Marentes, M. E., & Bosch-Canto, V. (2022). November 2). Retinoblastoma: Review and new insights. Frontiers in oncology. Frontiers Media S A. https:\/\/doi.org\/10.3389\/fonc.2022.963780","journal-title":"Frontiers Media S A"},{"key":"2015_CR93","doi-asserted-by":"publisher","unstructured":"Han, H., Sun, X., Guo, X., Wen, J., Zhao, X., & Zhou, W. (2025). CRISPR\/Cas9 technology in tumor research and drug development application progress and future prospects. Frontiers in Pharmacology, 16, 1552741 https:\/\/doi.org\/10.3389\/fbioe.2022.895713","DOI":"10.3389\/fbioe.2022.895713"},{"key":"2015_CR94","doi-asserted-by":"publisher","unstructured":"Turner, E., Chen, L., Foulke, J. G., Gu, Z., & Tian, F. (2022). CRISPR\/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK\/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy. Cancers, 14(21 https:\/\/doi.org\/10.3389\/fbioe.2022.895713","DOI":"10.3389\/fbioe.2022.895713"},{"key":"2015_CR95","doi-asserted-by":"publisher","unstructured":"Asmamaw Mengstie, M. (2022, May 12). Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A. https:\/\/doi.org\/10.1016\/j.bcp.2023.115555","DOI":"10.1016\/j.bcp.2023.115555"},{"key":"2015_CR96","doi-asserted-by":"publisher","unstructured":"Farzanehpour, M., Miri, A., Alvanegh, A. G., & Gouvarchinghaleh, H. E. (2023, June 1). Viral Vectors, Exosomes, and Vexosomes: Potential armamentarium for delivering CRISPR\/Cas to cancer cells. Biochemical Pharmacology. Elsevier Inc. https:\/\/doi.org\/10.1016\/j.bcp.2023.115555","DOI":"10.1016\/j.bcp.2023.115555"},{"key":"2015_CR97","unstructured":"Liu, L., Yang, J., Song, J., Yang, X., Niu, L., Cai, Z., \u2026 Deng, Y. (2024). AAVDiff:Experimental Validation of Enhanced Viability and Diversity in Recombinant Adeno-Associated Virus (AAV) Capsids through Diffusion Generation. Retrieved from http:\/\/arxiv.org\/abs\/2404.10573."},{"key":"2015_CR98","doi-asserted-by":"publisher","unstructured":"Xu, L., Yao, S., Ding, Y. E., Xie, M., Feng, D., Sha, P., \u2026 Yao, Y. (2024, December 1). Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases:from bench to bedside. Journal of translational medicine. https:\/\/doi.org\/10.1186\/s12967-024-05661-2.","DOI":"10.1186\/s12967-024-05661-2."},{"key":"2015_CR99","unstructured":"Guna, S., Gurazada, R., Kennedy, H. M., Braatz, R. D., Mehrman, S. J., Polson, S. W., & Rombel, I. T. (n.d.). HEK-Omics: The promise of omics to optimize HEK293 for recombinant adeno-associated virus (rAAV) gene therapy manufacturing"},{"key":"2015_CR100","unstructured":"Bal, V., Wolfrum, J. M., Barone, P. W., Springs, S. L., Sinskey, A. J., Kotin, R. M., & Braatz, R. D. (n.d.). Selective Enrichment of Full AAV Capsids."},{"key":"2015_CR101","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2022.0051","author":"S Demirci","year":"2022","unstructured":"Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022). October 1). Advances in CRISPR delivery methods: Perspectives and challenges. CRISPR Journal Mary Ann Liebert Inc. https:\/\/doi.org\/10.1089\/crispr.2022.0051","journal-title":"CRISPR Journal Mary Ann Liebert Inc"},{"issue":"6","key":"2015_CR102","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","volume":"52","author":"D Wilbie","year":"2019","unstructured":"Wilbie, D., Walther, J., & Mastrobattista, E. (2019). Delivery aspects of CRISPR\/Cas for in vivo genome editing. Accounts of Chemical Research, 52(6), 1555\u20131564. https:\/\/doi.org\/10.1021\/acs.accounts.9b00106","journal-title":"Accounts of Chemical Research"},{"key":"2015_CR103","doi-asserted-by":"publisher","unstructured":"Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018). Delivering crispr: A review of the challenges and approaches. Drug delivery. Taylor and Francis Ltd. https:\/\/doi.org\/10.1080\/10717544.2018.1474964","DOI":"10.1080\/10717544.2018.1474964"},{"key":"2015_CR104","doi-asserted-by":"publisher","unstructured":"Dong, W., & Kantor, B. (2021, July 1). Lentiviral vectors for delivery of gene-editing systems based on crispr\/cas: Current state and perspectives. Viruses. MDPI https:\/\/doi.org\/10.3390\/v13071288","DOI":"10.3390\/v13071288"},{"key":"2015_CR105","doi-asserted-by":"publisher","unstructured":"Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli,A., \u2026 Taheri, M. (2022, December 1). Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy. Molecular Cancer. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12943-021-01487-4.","DOI":"10.1186\/s12943-021-01487-4."},{"key":"2015_CR106","doi-asserted-by":"publisher","unstructured":"S\u00f8ndergaard, J. N., Geng, K., Sommerauer, C., Atanasoai, I., Yin, X., & Kutter, C. (2020). Successful delivery of large-size CRISPR\/Cas9 vectors in hard-to-transfect human cells using small plasmids. Communications Biology, 3(1). https:\/\/doi.org\/10.1038\/s42003-020-1045-7","DOI":"10.1038\/s42003-020-1045-7"},{"key":"2015_CR107","doi-asserted-by":"publisher","unstructured":"Yu, W., Wang, Y., Li, S., Dai, Y., Li, Y., Zhang, X., \u2026 Bi, C. (2025). Optimized dual-AAV base editor delivery system with enhanced editing efficiency and virion production titer. Synthetic and Systems Biotechnology, 10(3), 697\u2013706. https:\/\/doi.org\/10.1016\/j.synbio.2025.03.007.","DOI":"10.1016\/j.synbio.2025.03.007."},{"key":"2015_CR108","doi-asserted-by":"publisher","unstructured":"Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023). March 1). Delivery challenges for CRISPR\u2014Cas9 genome editing for Duchenne muscular dystrophy. Biophysics reviews. American Institute of Physics. https:\/\/doi.org\/10.1063\/5.0131452","DOI":"10.1063\/5.0131452"},{"key":"2015_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-012-0678-1","author":"AJ Mellott","year":"2013","unstructured":"Mellott, A. J., Forrest, M. L., & Detamore, M. S. (2013). March). Physical non-viral gene delivery methods for tissue engineering. Annals of Biomedical Engineering. https:\/\/doi.org\/10.1007\/s10439-012-0678-1","journal-title":"Annals of Biomedical Engineering"},{"issue":"6","key":"2015_CR110","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"B Yip","year":"2020","unstructured":"Yip, B. (2020). Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules, 10(6), 839. https:\/\/doi.org\/10.3390\/biom10060839","journal-title":"Biomolecules"},{"key":"2015_CR111","doi-asserted-by":"publisher","unstructured":"Du, Y., Liu, Y., Hu, J., Peng, X., & Liu, Z. (2023, November 1). CRISPR\/Cas9 systems: Delivery technologies and biomedical applications. Asian Journal of Pharmaceutical Sciences. Shenyang Pharmaceutical University. https:\/\/doi.org\/10.1016\/j.ajps.2023.100854","DOI":"10.1016\/j.ajps.2023.100854"},{"key":"2015_CR112","doi-asserted-by":"publisher","unstructured":"Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C. X. (2022, February 1). Lipid Nanoparticles for Drug Delivery. Advanced NanoBiomed Research. John Wiley and Sons Inc. https:\/\/doi.org\/10.1002\/anbr.202100109","DOI":"10.1002\/anbr.202100109"},{"key":"2015_CR113","doi-asserted-by":"publisher","unstructured":"Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023). November 8). Lipid-Based nanoparticles for Drug\/Gene delivery: An overview of the production techniques and difficulties encountered in their industrial development. ACS materials Au. American Chemical Society. https:\/\/doi.org\/10.1021\/acsmaterialsau.3c00032","DOI":"10.1021\/acsmaterialsau.3c00032"},{"issue":"5","key":"2015_CR114","doi-asserted-by":"publisher","first-page":"94907422","DOI":"10.26599\/NR.2025.94907422","volume":"18","author":"HQ Truong","year":"2025","unstructured":"Truong, H. Q., & Meng, F. (2025). Unlocking the full therapeutic potential of lipid nanoparticles through extrahepatic delivery. Nano Research, 18(5), 94907422. https:\/\/doi.org\/10.26599\/NR.2025.94907422","journal-title":"Nano Research"},{"key":"2015_CR115","doi-asserted-by":"publisher","unstructured":"Rai, R., Alwani, S., & Badea, I. (2019, April 1). Polymeric nanoparticles in gene therapy: New avenues of design and optimization for delivery applications. Polymers. MDPI AG. https:\/\/doi.org\/10.3390\/polym11040745","DOI":"10.3390\/polym11040745"},{"key":"2015_CR116","doi-asserted-by":"publisher","unstructured":"Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. Van, Grimme, C. J.,Dalal, R. J., \u2026 Reineke, T. M. (2021, September 22). Polymeric Delivery of Therapeutic Nucleic Acids. Chemical Reviews. American Chemical Society. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00997.","DOI":"10.1021\/acs.chemrev.0c00997."},{"key":"2015_CR117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jconrel.2021.01.014","volume":"331","author":"AIS van den Berg","year":"2021","unstructured":"van den Berg, A. I. S., Yun, C. O., Schiffelers, R. M., & Hennink, W. E. (2021). Polymeric delivery systems for nucleic acid therapeutics: Approaching the clinic. Journal of Controlled Release, 331, 121\u2013141. https:\/\/doi.org\/10.1016\/j.jconrel.2021.01.014","journal-title":"Journal of Controlled Release"},{"key":"2015_CR118","doi-asserted-by":"publisher","unstructured":"Ryu, J. Y., Won, E. J., Lee, H. A. R., Kim, J. H., Hui, E., Kim, H. P., & Yoon, T. J. (2020). Ultrasound-activated particles as CRISPR\/Cas9 delivery system for androgenic alopecia therapy. Biomaterials, 232. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119736","DOI":"10.1016\/j.biomaterials.2019.119736"},{"key":"2015_CR119","doi-asserted-by":"publisher","unstructured":"Hansen-Bruhn, M., de \u00c1vila, B. E. F., Beltr\u00e1n-Gast\u00e9lum, M., Zhao, J., Ram\u00edrez-Herrera,D. E., Angsantikul, P., \u2026 Wang, J. (2018). Active Intracellular Delivery of a Cas9\/sgRNA Complex Using Ultrasound-Propelled Nanomotors. Angewandte Chemie - International Edition, 57(10), 2657\u20132661. https:\/\/doi.org\/10.1002\/anie.201713082.","DOI":"10.1002\/anie.201713082."},{"key":"2015_CR120","doi-asserted-by":"publisher","unstructured":"Xie, R., Wang, Y., & Gong, S. (2021, September 21). External stimuli-responsive nanoparticles for spatially and temporally controlled delivery of CRISPR-Cas genome editors. Biomaterials Science. Royal Society of Chemistry. https:\/\/doi.org\/10.1039\/d1bm00558h","DOI":"10.1039\/d1bm00558h"},{"key":"2015_CR121","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43465","author":"AK Fajrial","year":"2020","unstructured":"Fajrial, A. K., He, Q. Q., Wirusanti, N. I., Slansky, J. E., & Ding, X. (2020). A review of emerging physical transfection methods for CRISPR\/Cas9-mediated gene editing. Theranostics Ivyspring International Publisher. https:\/\/doi.org\/10.7150\/thno.43465","journal-title":"Theranostics Ivyspring International Publisher"},{"key":"2015_CR122","doi-asserted-by":"publisher","unstructured":"Suda, T., Yokoo, T., Kanefuji, T., Kamimura, K., Zhang, G., & Liu, D. (2023, April 1). Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances. Pharmaceutics. MDPI. https:\/\/doi.org\/10.3390\/pharmaceutics15041111","DOI":"10.3390\/pharmaceutics15041111"},{"issue":"3","key":"2015_CR123","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/crispr.2021.0134","volume":"5","author":"T Rathbone","year":"2022","unstructured":"Rathbone, T., Ates, I., Fernando, L., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022). Electroporation-Mediated delivery of Cas9 ribonucleoproteins results in high levels of gene editing in primary hepatocytes. CRISPR Journal, 5(3), 397\u2013409. https:\/\/doi.org\/10.1089\/crispr.2021.0134","journal-title":"CRISPR Journal"},{"key":"2015_CR124","doi-asserted-by":"publisher","unstructured":"Padayachee, J., & Singh, M. (2020). Therapeutic applications of CRISPR\/Cas9 in breast cancer and delivery potential of gold nanomaterials. Nanobiomedicine. SAGE Publications Ltd. https:\/\/doi.org\/10.1177\/1849543520983196","DOI":"10.1177\/1849543520983196"},{"key":"2015_CR125","doi-asserted-by":"publisher","unstructured":"Li, J., Wang, J., & Chen, Z. (2025, December 1). Emerging role of exosomes in cancer therapy: progress and challenges. Molecular cancer. https:\/\/doi.org\/10.1186\/s12943-024-02215-4","DOI":"10.1186\/s12943-024-02215-4"},{"key":"2015_CR126","doi-asserted-by":"publisher","unstructured":"Hashim, H. T., Alhatemi, A. Q. M., Fatima, T., Haque, T., Sulaiman, F. A., Ganim,M., \u2026 Al-Obaidi, A. (2025, December 1). Efficacy of CRISPR-Cas9 gene editing for targeting KRAS mutations in pancreatic cancer: a systematic review. Discover Oncology. Springer Science and Business Media B.V. https:\/\/doi.org\/10.1007\/s12672-025-02231-w.","DOI":"10.1007\/s12672-025-02231-w."},{"key":"2015_CR127","doi-asserted-by":"publisher","unstructured":"Cho, H., Yoo, M., Pongkulapa, T., Rabie, H., Muotri, A. R., Yin, P. T., \u2026 Lee, K.(2024). Magnetic Nanoparticle-Assisted Non\u2010Viral CRISPR\u2010Cas9 for Enhanced Genome Editing to Treat Rett Syndrome. Advanced Science, 11(24). https:\/\/doi.org\/10.1002\/advs.202306432.","DOI":"10.1002\/advs.202306432."},{"key":"2015_CR128","doi-asserted-by":"publisher","unstructured":"Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., \u2026 Li, S. (2024). Biomaterial-Based CRISPR\/Cas9 Delivery Systems for Tumor Treatment. Biomaterials Research, 28. https:\/\/doi.org\/10.34133\/bmr.0023.","DOI":"10.34133\/bmr.0023."},{"key":"2015_CR129","doi-asserted-by":"publisher","unstructured":"Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster,E., \u2026 June, C. H. (2020). CRISPR-engineered T cells in patients with refractory cancer.Science, 367(6481). https:\/\/doi.org\/10.1126\/science.aba7365.","DOI":"10.1126\/science.aba7365."},{"key":"2015_CR130","doi-asserted-by":"publisher","unstructured":"Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala,V., \u2026 Zhang, F. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnology, 31(9), 827\u2013832. https:\/\/doi.org\/10.1038\/nbt.2647.","DOI":"10.1038\/nbt.2647."},{"key":"2015_CR131","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR\/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11, 1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"2015_CR132","doi-asserted-by":"publisher","unstructured":"Roy, S. (2021). Immune responses to CRISPR-Cas protein (pp. 213\u2013229). https:\/\/doi.org\/10.1016\/bs.pmbts.2020.12.003","DOI":"10.1016\/bs.pmbts.2020.12.003"},{"key":"2015_CR133","doi-asserted-by":"publisher","unstructured":"Yang, Y., Xu, J., Ge, S., & Lai, L. (2021, March 3). CRISPR\/Cas: Advances, Limitations,and Applications for Precision Cancer Research. Frontiers in Medicine. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fmed.2021.649896.","DOI":"10.3389\/fmed.2021.649896."},{"key":"2015_CR134","doi-asserted-by":"publisher","unstructured":"Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., \u2026 Anderson,D. G. (2014). Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 32(6), 551\u2013553. https:\/\/doi.org\/10.1038\/nbt.2884.","DOI":"10.1038\/nbt.2884."},{"issue":"3","key":"2015_CR135","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13534-021-00199-4","volume":"11","author":"VA Sioson","year":"2021","unstructured":"Sioson, V. A., Kim, M., & Joo, J. (2021). Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomedical Engineering Letters, 11(3), 217\u2013233. https:\/\/doi.org\/10.1007\/s13534-021-00199-4","journal-title":"Biomedical Engineering Letters"},{"key":"2015_CR136","doi-asserted-by":"publisher","unstructured":"Ding, S., Liu, J., Han, X., & Tang, M. (2023, November 1). CRISPR\/Cas9-Mediated Genome Editing in Cancer Therapy. International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI). https:\/\/doi.org\/10.3390\/ijms242216325.","DOI":"10.3390\/ijms242216325."},{"key":"2015_CR137","doi-asserted-by":"publisher","unstructured":"Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi,E., Eskandari, F., \u2026 Mokhtari-Farsani, A. (2024, December 1). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.Molecular Cancer. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12943-023-01925-5.","DOI":"10.1186\/s12943-023-01925-5."},{"key":"2015_CR138","doi-asserted-by":"publisher","unstructured":"Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024). CRISPR\/Cas9: an overview of recent developments and applications in cancer research. International Journal of Surgery https:\/\/doi.org\/10.1097\/js9.0000000000001081","DOI":"10.1097\/js9.0000000000001081"},{"key":"2015_CR139","doi-asserted-by":"publisher","unstructured":"Saffari Natanzi, A., Poudineh, M., Karimi, E., Khaledi, A., & Haddad Kashani, H.(2025). Innovative approaches to combat antibiotic resistance: integrating CRISPR\/Cas9 and nanoparticles against biofilm-driven infections. BMC Medicine 2025 23:1, 23(1), 1\u201324. https:\/\/doi.org\/10.1186\/S12916-025-04323-4.","DOI":"10.1186\/S12916-025-04323-4."},{"key":"2015_CR140","doi-asserted-by":"publisher","unstructured":"Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J.K., \u2026 Singh, V. (2022). Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of Controlled Release, 343, 703\u2013723. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.005.","DOI":"10.1016\/j.jconrel.2022.02.005."},{"key":"2015_CR141","doi-asserted-by":"publisher","unstructured":"Aliu Olalekan Olatunji, Janet Aderonke Olaboye, Chukwudi Cosmos Maha, Tolulope Olagoke Kolawole, & Samira Abdul. (2024). Next-Generation strategies to combat antimicrobial resistance: Integrating genomics, CRISPR, and novel therapeutics for effective treatment.Engineering Science & Technology Journal, 5(7), 2284\u20132303. https:\/\/doi.org\/10.51594\/estj.v5i7.1344.","DOI":"10.51594\/estj.v5i7.1344."},{"key":"2015_CR142","doi-asserted-by":"publisher","unstructured":"Zhu, J., Zhou, J., Tang, Y., Huang, R., Lu, C., Qian, K., \u2026 Chen, S. (2025). Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell International 2025 25:1, 25(1), 1\u201315. https:\/\/doi.org\/10.1186\/S12935-025-03938-0.","DOI":"10.1186\/S12935-025-03938-0."},{"key":"2015_CR143","doi-asserted-by":"publisher","first-page":"1546172","DOI":"10.3389\/FIMMU.2025.1546172\/BIBTEX","volume":"16","author":"S G\u00f3mez-Melero","year":"2025","unstructured":"G\u00f3mez-Melero, S., Hassouneh, F., Vallejo-Berm\u00fadez, I. M., Ag\u00fcera-Morales, E., Solana, R., & Caballero-Villarraso, J. (2025). Tandem CAR-T cell therapy: Recent advances and current challenges. Frontiers in Immunology, 16, 1546172. https:\/\/doi.org\/10.3389\/FIMMU.2025.1546172\/BIBTEX","journal-title":"Frontiers in Immunology"},{"key":"2015_CR144","doi-asserted-by":"publisher","unstructured":"Kavousinia, P., Ahmadi, M. H., Sadeghian, H., & Hosseini Bafghi, M. (2024). Therapeutic potential of CRISPR\/CAS9 genome modification in T cell-based immunotherapy of cancer.Cytotherapy, 26(5), 436\u2013443. https:\/\/doi.org\/10.1016\/J.JCYT.2024.02.014.","DOI":"10.1016\/J.JCYT.2024.02.014."},{"issue":"4","key":"2015_CR145","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1007\/S00210-024-03480-2","volume":"398:4","author":"S Noruzi","year":"2024","unstructured":"Noruzi, S., Mohammadi, R., & Jamialahmadi, K. (2024). CRISPR\/Cas9 system: A novel approach to overcome chemotherapy and radiotherapy resistance in cancer. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology 2024, 398:4(4), 3373\u20133408. https:\/\/doi.org\/10.1007\/S00210-024-03480-2. 398.","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology 2024"},{"issue":"1","key":"2015_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12672-025-03383-5","volume":"16:1","author":"H Noormohamadi","year":"2025","unstructured":"Noormohamadi, H., Samarkhazan, S., kargar, H., Maroufi, M., Servatian, F., N., & Davami, F. (2025). CRISPR\/Cas technologies in pancreatic cancer research and therapeutics: Recent advances and future outlook. Discover Oncology 2025, 16:1(1), 1\u201339. https:\/\/doi.org\/10.1007\/S12672-025-03383-5. 16.","journal-title":"Discover Oncology 2025"},{"key":"2015_CR147","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03480-2","author":"S Noruzi","year":"2024","unstructured":"Noruzi, S., Mohammadi, R., & Jamialahmadi, K. (2024). CRISPR\/Cas9 system: A novel approach to overcome chemotherapy and radiotherapy resistance in cancer. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. https:\/\/doi.org\/10.1007\/s00210-024-03480-2","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"issue":"1","key":"2015_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12672-025-01816-9","volume":"16:1","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi, N., Heidari, R., Farhadi, A., Chamanara, M., Farahani, N., Vahidi, M., & Behroozi, J. (2025). Next-generation sequencing in cancer diagnosis and treatment: Clinical applications and future directions. Discover Oncology 2025, 16:1(1), 1\u201320. https:\/\/doi.org\/10.1007\/S12672-025-01816-9. 16.","journal-title":"Discover Oncology 2025"},{"issue":"1","key":"2015_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11033-025-10361-1","volume":"52:1","author":"SS Alqarni","year":"2025","unstructured":"Alqarni, S. S., & Khan, N. U. (2025). Integrating alternative therapies in overcoming chemotherapy resistance in tumors. Molecular Biology Reports 2025, 52:1(1), 1\u201315. https:\/\/doi.org\/10.1007\/S11033-025-10361-1. 52.","journal-title":"Molecular Biology Reports 2025"},{"key":"2015_CR150","doi-asserted-by":"publisher","unstructured":"Zhu, X., Qian, Y., Tang, Q., Li, J., Geng, Y., Gong, S., & Jin, C. (2025). Research Advances of Extrachromosomal Circular DNA in Breast Cancer. Cancer Medicine, 14(19), e71285. https:\/\/doi.org\/10.1002\/CAM4.71285.","DOI":"10.1002\/CAM4.71285."},{"key":"2015_CR151","doi-asserted-by":"publisher","unstructured":"Selvakumar, S. C., Preethi, K. A., Ross, K., Tusubira, D., Khan, M. W. A., Mani,P., \u2026 Sekar, D. (2022, December 1). CRISPR\/Cas9 and next generation sequencing in the personalized treatment of Cancer. Molecular Cancer. BioMed Central Ltd. https:\/\/doi.org\/10.1186\/s12943-022-01565-1.","DOI":"10.1186\/s12943-022-01565-1."},{"issue":"2","key":"2015_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00432-025-06105-0","volume":"151:2","author":"J Wang","year":"2025","unstructured":"Wang, J., Gao, G., Tian, C., Zhang, J., Jiao, D. C., & Liu, Z. Z. (2025). Next-generation sequencing based deep learning model for prediction of HER2 status and response to HER2-targeted neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology 2025, 151:2(2), 1\u201311. https:\/\/doi.org\/10.1007\/S00432-025-06105-0. 151.","journal-title":"Journal of Cancer Research and Clinical Oncology 2025"},{"issue":"7","key":"2015_CR153","doi-asserted-by":"publisher","first-page":"e70243","DOI":"10.1002\/MCO2.70243","volume":"6","author":"T Wolde","year":"2025","unstructured":"Wolde, T., Bhardwaj, V., & Pandey, V. (2025). Current bioinformatics tools in precision oncology. MedComm, 6(7), e70243. https:\/\/doi.org\/10.1002\/MCO2.70243;WGROUP:STRING:PUBLICATION.","journal-title":"MedComm"},{"key":"2015_CR154","doi-asserted-by":"publisher","first-page":"117693512211401","DOI":"10.1177\/11769351221140102","volume":"21","author":"E Maserat","year":"2022","unstructured":"Maserat, E. (2022). Integration of artificial intelligence and CRISPR\/Cas9 system for vaccine design. Cancer Informatics, 21, 11769351221140102. https:\/\/doi.org\/10.1177\/11769351221140102","journal-title":"Cancer Informatics"},{"key":"2015_CR155","doi-asserted-by":"publisher","unstructured":"Lou, E., Choudhry, M. S., Starr, T. K., Folsom, T. D., Bell, J., Rathmann, B., \u2026Moriarity, B. S. (2025). Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre,phase 1 trial. The Lancet Oncology, 26(5), 559\u2013570. https:\/\/doi.org\/10.1016\/S1470-2045(25)00083-X.","DOI":"10.1016\/S1470-2045(25)00083-X."},{"issue":"1","key":"2015_CR156","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40164-023-00457-4","volume":"12","author":"C Chen","year":"2023","unstructured":"Chen, C., Wang, Z., & Qin, Y. (2023). CRISPR\/Cas9 system: Recent applications in immuno-oncology and cancer immunotherapy. Experimental Hematology & Oncology, 12(1), 95. https:\/\/doi.org\/10.1186\/s40164-023-00457-4","journal-title":"Experimental Hematology & Oncology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02015-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:22:38Z","timestamp":1780482158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02015-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":156,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02015-1","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"29 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human subjects or animals were involved during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}